Reply to "Comments on Cost Analysis of Risperidone Versus Olanzapine"

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Duggal and Gandotra make some important observations on our cost analysis of risperidone and olanzapine. Our study was designed to evaluate drug treatment costs in a UK hospital setting. Costs incurred after discharge were not recorded, and it is possible that differences in postdischarge outcome and resource utilization could have led to rather different conclusions. However, we are not aware of any clinical trial data that suggest different long-term outcome for risperidone and olanzapine.